AstraZeneca's Brilinta tops aspirin in reducing stroke risks by Kyle Blankenship Monday, January 27, 2020 Stinging from a previous trial failure in 2016, AstraZeneca's Brilinta topped solo aspirin in slicing CV risks in heart attack and stroke patients.
Major drugmakers likely to benefit from heart failure gold rush by Kyle Blankenship Tuesday, January 21, 2020 An SGLT2 arms race is currently underway for heart failure patients, and not without reason: the market will likely continue to boom this decade.
Novo's Ozempic scores major win with heart-helping FDA approval by Kyle Blankenship Friday, January 17, 2020 Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.
AstraZeneca's Farxiga speeds toward pioneering CV approval by Kyle Blankenship Monday, January 6, 2020 With a nod in heart failure patients already secured, AstraZeneca's Farxiga has now landed a priority review in patients with or without diabetes.
Drugmakers' oncology, rare diseases rebrands may stay in 2020 by Kyle Blankenship Thursday, December 19, 2019 Lately, pharmas have been rebranding—more often than not, around oncology, rare diseases or both—and more could join the fold in 2020.
Lilly, BI's Jardiance whiffs in CV trial chasing Farxiga by Kyle Blankenship Friday, December 13, 2019 Eli Lilly and Boehringer's Jardiance fell short in a heart failure trial in patients with or without diabetes—a test AZ's rival Farxiga recently aced.
AZ launches U.S. awareness tour for diabetes, heart failure link by Beth Snyder Bulik Monday, December 2, 2019 AstraZeneca is hitting the road to ramp up its education and awareness around the link between Type 2 diabetes and heart failure.
AHA: AZ's Farxiga data show big benefit in non-diabetics by Kyle Blankenship Saturday, November 16, 2019 AstraZeneca's Farxiga is touting its heart failure data in patients with or without diabetes, but results in non-diabetics look particularly strong.
Eli Lilly, Boehringer's SGLT2 med hits snag in Type 1 diabetes by Kyle Blankenship Thursday, November 14, 2019 Eli Lilly and Boehringer Ingelheim failed to persuade an FDA expert panel that their SGLT2 med, Jardiance, could be repurposed for Type 1 diabetes.
J&J taps kidney specialist Vifor for Invokana marketing help by Kyle Blankenship Monday, November 4, 2019 J&J scored a win for Invokana in September with an FDA OK to treat kidney disease. Now, as a newcomer to the field, J&J is seeking marketing backup.
